ALS2 and leukemia: Finally, database screening showed that augmented ALS2 expression correlates with poor patient survival in a subgroup of cancers, including adrenocortical carcinoma, papillary renal cell carcinoma and lung squamous cell carcinoma, although contrasting results were found in others, such as leukemia and CCRCC (Supplementary Fig. 4).